Press Releases from 2008 and earlier

Mon, 12/22/2008 - 07:00

Evolva submits CTA for first-in-man study with new cardiovascular drug

Basel, Switzerland, December 2008 – Evolva SA, an international biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, today announced the filing of a Clinical Trial Application (CTA) for EV-077–3201–2TBS. This is a new chemical entity that is being developed for reduction of cardiovascular morbidity and mortality in patients who are hypo-responders or resistant to Aspirin and/or Clopidogrel. It is also being developed for treatment of proteinuric kidney diseases.

Fri, 12/12/2008 - 07:00

Evolva opens US Research Center

Basel, Switzerland, and Palo Alto, CA, USA , December 12th 2008 – Evolva SA, a biotech company that develops drugs with genetic chemistry, announced the opening of a research center in Palo Alto, CA, that will serve as the US center of operations for wholly-owned subsidiary Genetic Chemistry, Inc. (GCI).

Tue, 11/04/2008 - 07:00

Evolva receives funding from the Global Cardiovascular Innovation Center

Basel, Switzerland, November 2008 – Evolva today announced that it has received a $288,000 award from the Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). The funding is to advance the development of Evolva’s EV-077 compound series for cardiovascular disease and to explore the formation of a dedicated cardiovascular clinical unit to be based in Cleveland, Ohio.

Tue, 09/30/2008 - 07:00

Evolva appoints new advisors

Dr. Jessica Mann, MD, PhD is a cardiologist with long-standing experience in the cardiovascular and metabolic drug development arena; in particular as Medical Director and member of the Management group at Speedel, which has recently been sold to Novartis for $880 million. Before joining Speedel, Jessica worked for Roche and Novartis.

Tue, 08/12/2008 - 07:00

Evolva India Announces 3 Collaborations

Evolva facility recognized by the Government

Secunderabad, India, August 2008 – Evolva’s Genetic Chemistry Laboratory, has received recognition from the Government of India’s Department of Science and Industrial Research (DSIR).

Mon, 05/19/2008 - 17:14

Evolva Subsidiary Signs $22.8 Million Antibacterial Contract with US Army Research Office, Builds Out US Operations

Genetic Chemistry Inc. (Palo Alto, USA), a subsidiary of Evolva SA (Basel, Switzerland) announced today that it has signed a contract with the US Army Research Office (ARO), working in conjunction with the Defense Threat Reduction Agency (DTRA), to discover novel therapeutics against the gram negative bacterial pathogen Burkholderia pseudomallei (a CDC category B bioterrorism agent that causes the disease melioidosis). Over the contract period funding could amount to $22.8 million.

Sat, 09/15/2007 - 07:00

New CFO at Evolva

Jakob D. Hansen has joined Evolva SA, the Swiss-based biotech company, as Chief Financial Officer.

Jakob, a Danish national, has extensive experience from both the biotech and the financial industry. Before joining Evolva, he was a financial advisor to several life science companies in Denmark. From 1999 to 2005, he was CFO at Zealand Pharma in Copenhagen, responsible for managing four financing rounds and two major licensing negotiations.

Fri, 07/20/2007 - 07:00

Evolva and Summit sign collaboration to develop anti-infectives

Evolva SA and Summit have entered into a collaboration for co-development of immuno-modulators for the treatment and prevention of certain infectious diseases. The aim of the collaboration is to bring one or more compounds to the IND stage, at which point the two parties will decide the further development.

Fri, 07/13/2007 - 07:00

Sandy Dobbie becomes new chairman at Evolva

Sandy Dobbie has been elected new chairman at Evolva SA. The former chairman, Jean-Philippe Tripet, Managing Partner of Aravis Venture, will remain a member of the board of Evolva.

Mon, 01/01/2007 - 07:00

Evolva led consortium receives a € 3.4 million Cancer research grant from EC

Evolva led consortium received € 3.4 million for funding a three year cancer research program on protein-protein interaction. The project brings together some of Europe's leading biotech SME's and several highly recognized academic institutes. By combining distinct chemical approaches and testing them on different targets a series of innovative small-ligand tools and libraries that allow new approaches to the inhibition of PPI in cancer will be developed. The project will begin January 2007.

Wed, 12/20/2006 - 07:00

Evolva Announces Collaboration with Functional Genetics on $ 28 Million Award from the United States Defense Threat Reduction Agency

Evolva Biotech SA (Allschwil, Switzerland) a biotech company focused on the discovery and development of drugs based on genetic chemistry approaches today announced that it has entered an agreement with Functional Genetics, Inc. (Gaithersburg, Maryland) on a $ 28 million award from the United States Defense Threat Reduction Agency (DTRA) for the discovery and development of therapeutics that improve the ability of humans to resist haemorrhagic fever viruses, in particular Ebola.

Fri, 12/01/2006 - 07:00

Evolva raises CHF 12 million in new equity financing

Evolva SA has received binding commitments for CHF 12 million (USD 10.3 million) in a second round of its Series A financing. In March 2005, Evolva completed a first closing of CHF 21.5 million, led by Aravis. Co-investors were Novartis Ventures, Yamanouchi Ventures (now Astellas Ventures), APIDC-VC, Danish Innovation Investment, Seed Capital and VaekstFonden (now Sunstone Capital). Evolva has now raised an additional CHF 12 million from the same group of investors.

Wed, 11/08/2006 - 07:00

Evolva Announces $26.7 Million Award from the United States Defense Threat Reduction Agency

Evolva Biotech SA (Allschwil, Switzerland) a biotech company focused on the discovery and development of drugs based on genetic chemistry approaches today announced that it has received a $26.7 million award from the United States Defense Threat Reduction Agency (DTRA) for the discovery and development of therapeutics that improve the ability of humans to resist diverse pathogens, in particular potential biowarfare or bioterrorism agents.

Fri, 09/02/2005 - 07:00

Evolva Acquires Pharmaceutical Business of Poalis

Evolva SA (Allschwil, Switzerland) and Poalis A/S (Copenhagen, Denmark) announced today that Evolva has acquired the pharmaceutical business and associated assets of Poalis. The activities of Poalis in food and flavour chemicals and in agriculture do not form part of the transaction. Financial terms are not being disclosed.

Mon, 03/21/2005 - 07:00

APIDC-VC (India) invests in Evolva SA Evolva completes CHF 21.5 million A-round financing Evolva Establishes Indian Operations

Evolva Biotech SA (Allschwil, Switzerland) today announced that it has raised a further CHF 3.0 million (€2 million, $2.5 million) in a final closing of its A-round. New investor APIDC-VC led the financing with smaller participations from existing investors. The funding completes Evolva's A-round at CHF 21.5 million (In August 04 Evolva raised CHF 18.5 million in a first closing).

Mon, 08/16/2004 - 07:00

Evolva raises € 12 million A-round from International Investors

Evolva Biotech today announced that it has raised c. € 12 million (CHF 18.5 million, Dkr 90 million, US $ 14.9 million) of equity financing in a first-closing of its A-round. The financing was led by Aravis and included new investors Novartis Venture Fund, Yamanouchi Venture Capital and Dansk Innovationsinvestering. Existing investors Symbion Capital and Vaekstfonden also participated. In connection to the financing Evolva is establishing operations in Basel, Switzerland.

Press Releases from 2008 and earlier

Tools